A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Use of long-acting, reversible contraceptives is associated with an increased risk of certain cancers, a study suggests.

The following is a summary of “Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH ...